Clinical Trials for T-Cell Lymphoma

Dear Colleagues,

Peripheral T cell lymphomas are a group of rare but clinically and biologically diverse group of lymphomas. Current classifications include up to 85 subtypes grouped into broad categories, including primary cutaneous, nodal, extra nodal and leukemic presentations. Clinically, most are aggressive, but some subtypes have an indolent course. Current treatment paradigms have resulted in poor outcomes for these patients, necessitating the need for more effective treatments. While there have been therapeutic advances with specific agents approved for the treatment of T cell lymphomas, most treatments are noncurative. There is a huge unmet need to find more effective treatments with higher response rates and duration of response, both in the upfront and relapsed setting. An increased understanding of the biology and molecular mechanisms underlying these diseases, improved animal models to study targeted agents and collaborative efforts among academic centers are leading to the development of novel targeted therapies focused on treating these rare subtypes. 

This Special Issue is dedicated to key aspects of the most promising novel therapies in the treatment of T cell lymphomas. From bench to bedside, the focus will be on understanding the mechanisms of action and resistance of these agents and how best to tailor their use in the different subtypes. The key clinical aspects of clinical trials will be highlighted and critiqued for a better understanding of the application of this data. Finally, there will be a discussion on how the paradigm of “one treatment fits all” is changing towards a more molecularly defined approach for treating T cell lymphomas. 

I expect this to be an exciting issue and look forward to receiving your contributions.  

Dr. Jasmine Zain
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.